Pharma companies struggle to find the right balance between rigid quality systems and risk-based flexible quality systems.
Arik Gorban, Capgemini
Advertisement
Articles by Arik Gorban, Capgemini
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
2
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
3
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
4
Building a Pharmacist-Led Furoscix Workflow From Scratch
5